Is Ibogaine Legal in the UK?

Caught by definition, not by name

Ibogaine is not listed in the Misuse of Drugs Act 1971, the statute that names heroin, cocaine and LSD, nor in the Home Office’s list of drugs controlled under it. Searching for it there and finding nothing is what leads people to conclude it is legal.

It is caught instead by the Psychoactive Substances Act 2016, which took the opposite approach: rather than naming substances, it defines them. Anything capable of producing a psychoactive effect, other than the listed exemptions, falls inside. Ibogaine plainly does.

The Act was written to deal with novel substances that appeared faster than they could be scheduled. Ibogaine, which is neither novel nor synthetic, was swept in along with them.

What is and is not an offence

Every row below comes from the Psychoactive Substances Act 2016 itself. The maximum is the figure on indictment; a summary conviction in England and Wales carries twelve months.

How you would lawfully acquire it, and why you cannot

There is, for practical purposes, no lawful way to acquire ibogaine in the United Kingdom. One narrow exception exists and is described below; nobody appears to have used it.

Buying it means someone supplied it, which is an offence for them. Ordering it from abroad means importing it, which is an offence for you, and quantity does not rescue it: the Crown Prosecution Service is explicit that an amount consistent with personal use is still an offence. The one thing you may lawfully do is hold something you have already got, which is of no use to anyone planning anything.

Are UK retreats and facilitators lawful?

For anyone reading this to work out whether a UK retreat or facilitator is operating lawfully: it is sometimes argued that administering a substance to someone, rather than handing it over, is not “supply” and so falls outside section 5. The Act does not define supply, does not mention administration, and no court has settled the point. It does not matter here. Providing the substance to a participant is supply under section 5, and a facilitator who obtained it in the first place has already produced it, imported it, or possessed it with intent to supply. Each carries the same seven years. There is no facilitator exemption and no ceremonial exemption. There is a research exemption, but Schedule 2 confines it to approved scientific research, which means the approval of a recognised research ethics committee rather than a private protocol.

The medicinal products exemption

The Act exempts medicinal products, and this is the exemption people reach for.

It does not do what they think, and it is not empty either.

A medicinal product here takes its meaning from the Human Medicines Regulations 2012, which define one by presentation and by function: a substance presented as treating disease, or administered with a view to modifying a physiological function. There is no marketing-authorisation requirement anywhere in that definition. The Court of Appeal held in R v Chapman [2017] EWCA Crim 319 that whether a particular product qualifies must be decided case by case, on how it was manufactured and how it was intended to be supplied. That holding is recorded in the Home Office’s own statutory review of the Act.

The consequence is a split rather than a dead end. Ibogaine sold online as a psychoactive is not a medicinal product and the exemption does not touch it. Ibogaine manufactured to a prescriber’s order for a named patient would be.

Can a UK doctor prescribe ibogaine? The route nobody has walked

Canada, New Zealand and Australia are usually contrasted with the UK on the grounds that they describe a lawful route and Britain describes none. That contrast is wrong, and we published it ourselves.

A UK-registered doctor may order an unlicensed medicine, a “special”, under regulation 167 of the Human Medicines Regulations 2012, where no licensed product can meet an individual patient’s clinical need. It must be made or imported to that prescriber’s unsolicited order. Importing one from outside the EEA requires a Manufacturer’s “Specials” Licence and, under MHRA Guidance Note 14, at least 28 days’ written notice to the agency, which may object and thereby block it. Quantities are capped at 25 single administrations, or 25 courses of up to three months. Schedule 2 to the Psychoactive Substances Act then covers both ends of that transaction, because it exempts health care professionals acting in the course of their profession and anyone consuming a substance on a prescriber’s directions.

The strongest objection to all this is the threshold itself. Regulation 167 requires that no licensed product can meet the individual patient’s special clinical need, and for opioid dependence licensed products do exist: methadone and buprenorphine are both authorised in the UK. A prescriber would have to document why neither could serve this patient, for a drug with no product monograph and a known risk of fatal arrhythmia, and then survive the MHRA’s twenty-eight-day power to object. That is a high bar and it is meant to be.

We have found no evidence that any UK prescriber has cleared it for ibogaine. But the honest description of the British position is a route nobody has walked, not the absence of one.

Travelling for treatment

Travelling abroad for treatment is lawful, because the Act creates no offence of consuming a psychoactive substance and none of doing so overseas. Bringing anything back is a different matter: importation is an offence under section 8, and the fact that you obtained it lawfully in Mexico or the Netherlands has no bearing on it. Not every country draws that line where Britain does, and Singapore, in the status table, reaches its own citizens’ consumption abroad.

The status by country table sets out where the regimes differ, why ibogaine is illegal explains how the map came to look like this, and the treatment section covers the questions worth putting to any provider before you book.